<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="migraine/PMC5532325/results/search/drugs/results.xml">
  <result pre="to identify factors that can predict the treatment response to" exact="topiramate" post="prophylaxis in pediatric patients with migraine. Methods One hundred"/>
  <result pre="thirteen patients who were older than 7 years and received" exact="topiramate" post="for at least 3 months were recruited from the"/>
  <result pre="more than 50% in the number of migraine episodes after" exact="topiramate" post="treatment. Proposed predictive factors such as migraine characteristics including"/>
  <result pre="associated symptoms were not significantly related to a response to" exact="topiramate" post="treatment. Conclusions Migraine characteristics and associated symptoms were not"/>
  <result pre="associated symptoms were not significantly related to a response to" exact="topiramate" post="treatment. However, patients with significant impairment in daily activities"/>
  <result pre="activities showed significant benefit from the treatment, and so prophylactic" exact="topiramate" post="treatment should be strongly encouraged in this patient group."/>
  <result pre="strongly encouraged in this patient group. migraine predictive factor prophylaxis" exact="topiramate" post="INTRODUCTION Headache is one of the most common complaints"/>
  <result pre="require prophylactic medication. 7 Prophylactic treatment usually involves flunarizine, topiramate," exact="valproic acid," post="propranolol, or amitriptyline, and has been shown to be"/>
  <result pre="the predictive factors for a response to prophylactic therapy using" exact="topiramate" post="in pediatric patients. METHODS This study was approved by"/>
  <result pre="to understand and describe their symptoms adequately. Patients who received" exact="topiramate" post="prophylaxis for more than 3 months were included. The"/>
  <result pre="additional medication for migraine prophylaxis within 3 months after starting" exact="topiramate" post="prophylaxis, and 4) a period of discontinuation of topiramate"/>
  <result pre="starting topiramate prophylaxis, and 4) a period of discontinuation of" exact="topiramate" post="prophylaxis within the first 3 months after therapy initiation"/>
  <result pre="to receive prophylaxis were also included. Treatment was started with" exact="topiramate" post="at 1 mg/kg daily as a single dose before"/>
  <result pre="headache frequency of more than 50% compared to baseline. The" exact="topiramate" post="dosage was increased in increments of 50% of the"/>
  <result pre="if the frequency reduction did not reach 50% after receiving" exact="topiramate" post="for 3 months. We considered the following factors as"/>
  <result pre="and 10.3±2.8 years at disease onset, and their duration of" exact="topiramate" post="treatment was 8.3±5.1 months. The duration of disease was"/>
  <result pre="of determining if any of these factors were associated with" exact="topiramate" post="prophylaxis response in pediatric migraine patients. The presence of"/>
  <result pre="family history were not significantly related to a response to" exact="topiramate" post="treatment. The findings of previous studies have been inconsistent."/>
  <result pre="amitriptyline) 22 or were no associated with the response (for" exact="topiramate" post="and flunarizine). 23 24 Most studies have found no"/>
  <result pre="not related to the treatment response in two studies (for" exact="amitriptyline" post="and cinnarizine), 20 22 but one study suggested an"/>
  <result pre="was significantly more common in patients who responded well to" exact="topiramate" post="prophylaxis. However, a previous study of topiramate prophylaxis in"/>
  <result pre="responded well to topiramate prophylaxis. However, a previous study of" exact="topiramate" post="prophylaxis in adults utilizing the Migraine Disability Scale (MIDAS)"/>
  <result pre="results. Based on the findings to date, we suggest that" exact="topiramate" post="prophylaxis should be actively considered in patients even with"/>
  <result pre="attempt to discover predictive factors for a treatment response to" exact="topiramate" post="prophylaxis in pediatric patients. We also included dizziness as"/>
  <result pre="conducted in a single tertiary center targeting patients treated with" exact="topiramate" post="for at least 3 months, which means that the"/>
  <result pre="and associated symptoms were not related to the response to" exact="topiramate" post="treatment. However, impairment of daily activities was more common"/>
  <result pre="common in patients exhibiting good responses. Thus, prophylactic treatment with" exact="topiramate" post="should be actively considered in patients who experience impairment"/>
  <result pre="11292228 8 Bidabadi E Mashouf M A randomized trial of" exact="propranolol" post="versus sodium valproate for the prophylaxis of migraine in"/>
  <result pre="E Mashouf M A randomized trial of propranolol versus sodium" exact="valproate" post="for the prophylaxis of migraine in pediatric patients Paediatr"/>
  <result pre="Hershey AD Powers SW Bentti AL Degrauw TJ Effectiveness of" exact="amitriptyline" post="in the prophylactic management of childhood headaches Headache 2000"/>
  <result pre="Lim BC Chae JH Choi J et al. Comparison of" exact="flunarizine" post="and topiramate for the prophylaxis of pediatric migraines Eur"/>
  <result pre="Chae JH Choi J et al. Comparison of flunarizine and" exact="topiramate" post="for the prophylaxis of pediatric migraines Eur J Paediatr"/>
  <result pre="H Oksel F Erermis S Uyar M et al. Sodium" exact="valproate" post="prophylaxis in childhood migraine Headache 2002 42 819 822"/>
  <result pre="double-blind, placebo-controlled study to evaluate the efficacy and safety of" exact="topiramate" post="for migraine prevention in pediatric subjects 12 to 17"/>
  <result pre="Koch G Wessely P Long-term results of migraine prophylaxis with" exact="flunarizine" post="and beta-blockers Cephalalgia 1991 11 251 256 1790569 22"/>
  <result pre="Franz G Marecek S et al. Two different doses of" exact="amitriptyline" post="ER in the prophylaxis of migraine: long-term results and"/>
  <result pre="prognostic factors in a randomized controlled trial of acupuncture versus" exact="topiramate" post="treatment in patients with chronic migraine Clin J Pain"/>
  <result pre="as predictive factors of the response to migraine prophylaxis using" exact="topiramate" post="Total ( n=113) Responders ( n=70) Nonresponders ( n=43)"/>
  <result pre="Results of ordered logistic regression analysis of predictive factors for" exact="topiramate" post="prophylaxis Factors OR (95% CI) p Headache duration 0.87"/>
 </snippets>
</snippetsTree>
